ASSESSING CLINICAL EFFICACY AND TRIAL DESIGN PARAMETERS FOR TREATMENTS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A NOVEL QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL.

被引：0
|
作者：
Rieger, T. R. [1 ]
Allen, R. J. [1 ]
Musante, C. J. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
QSP-014
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [21] Efficacy of silymarin in patients with non-alcoholic fatty liver disease — the Siliver trial: a study protocol for a randomized controlled clinical trial
    Camila Ribeiro de Avelar
    Beatriz Vieira Coelho Nunes
    Betina da Silva Sassaki
    Mariana dos Santos Vasconcelos
    Lucivalda Pereira Magalhães de Oliveira
    André Castro Lyra
    Allain Amador Bueno
    Rosângela Passos de Jesus
    Trials, 24
  • [22] Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial
    de Avelar, Camila Ribeiro
    Nunes, Beatriz Vieira Coelho
    Sassaki, Betina da Silva
    Vasconcelos, Mariana dos Santos
    de Oliveira, Lucivalda Pereira Magalhaes
    Lyra, Andre Castro
    Bueno, Allain Amador
    de Jesus, Rosangela Passos
    TRIALS, 2023, 24 (01)
  • [23] Assessing the clinical and biochemical efficacy of alpha-lipoic acid in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled clinical trial
    Ebrahimi-Mameghani, Mehrangiz
    Asghari, Somayyeh
    Naeini, Fatemeh
    Taghizadeh, Mahdiyeh
    Hamedi-Shahraki, Soudabeh
    Amirkhizi, Farshad
    JOURNAL OF FUNCTIONAL FOODS, 2024, 114
  • [24] Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: A randomized clinical trial
    Zojaji, Seyyed Abbas
    Mozaffari, Hooman Mosannen
    Ghaderi, Pouya
    Zojaji, Faegheh
    Hadjzadeh, Mousa-Al-Reza
    Seyfimoqadam, Monireh
    Ghorbani, Ahmad
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58
  • [25] A novel mouse model for the study of pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
    Marin, Veronica
    Rosso, Natalia
    Dal Ben, Matteo
    Raseni, Alan
    Degrassi, Cristina
    Tiribelli, Claudio
    Gazzin, Silvia
    HEPATOLOGY, 2015, 62 : 1231A - 1231A
  • [26] Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development
    Jin, Yujin
    Heo, Kyung-Sun
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2023, 27 (04): : 299 - 310
  • [27] Prediction of Liver Fat in Non-Alcoholic Fatty Liver Disease Using Clinical and Genetic Markers
    Kotronen, Anna
    Peltonen, Markku
    Hakkarainen, Antti
    Sevastianova, Ksenia
    Orho-Melander, Marju
    Groop, Leif
    Ykijarvinen, Hannele
    DIABETES, 2009, 58 : A387 - A388
  • [28] Correlation of Clinical and Histopathologic Parameters with Ultrasonographic Grades in Pediatric Non-Alcoholic Fatty Liver Disease
    Kang, Bo-Kyeong
    Kim, Mimi
    Shin, Su-Jin
    Kim, Yong Joo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (47)
  • [29] Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
    Xue, Lanfeng
    Deng, Zhiliang
    Luo, Wenhui
    He, Xingxiang
    Chen, Yu
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [30] Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial
    Tian, Yanyan
    Zhou, Yuhao
    Liao, Wang
    Xia, Jiayue
    Hu, Qiaosheng
    Zhao, Qing
    Zhang, Rui
    Sun, Guiju
    Yang, Ligang
    Li, Lihua
    FOOD & FUNCTION, 2025, 16 (04) : 1389 - 1406
12345